Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BXRXNASDAQ:EYENNASDAQ:TCRTNASDAQ:XBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBXRXBaudax Bio$0.02$0.02$0.01▼$3.47$1.14M1.57281,029 shs310,872 shsEYENEyenovia$1.70-6.1%$1.20$0.85▼$124.80$4.90M0.76423,022 shs408,223 shsTCRTAlaunos Therapeutics$2.45-5.0%$2.59$1.31▼$11.50$4.02M-1.08136,345 shs6,319 shsXBIOXenetic Biosciences$2.91-2.3%$2.76$2.20▼$5.20$4.49M2.3113,357 shs802 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBXRXBaudax Bio0.00%0.00%0.00%0.00%0.00%EYENEyenovia-6.08%-3.95%+51.79%+0.59%-97.11%TCRTAlaunos Therapeutics-5.04%-7.89%0.00%+58.06%-77.10%XBIOXenetic Biosciences-0.34%-5.49%+2.50%-26.02%-24.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBXRXBaudax BioN/AN/AN/AN/AN/AN/AN/AN/AEYENEyenovia1.7025 of 5 stars2.05.00.00.02.20.01.3TCRTAlaunos Therapeutics0.3941 of 5 stars0.03.00.00.01.90.00.6XBIOXenetic Biosciences1.8179 of 5 stars0.05.00.00.03.00.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBXRXBaudax Bio 0.00N/AN/AN/AEYENEyenovia 2.00Hold$2.0017.65% UpsideTCRTAlaunos Therapeutics 0.00N/AN/AN/AXBIOXenetic Biosciences 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest BXRX, EYEN, XBIO, and TCRT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025XBIOXenetic BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/21/2025EYENEyenoviaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/20/2025XBIOXenetic BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBXRXBaudax Bio$1.27M0.90N/AN/A($14.93) per share0.00EYENEyenovia$67.06K73.08N/AN/A$16.32 per share0.10TCRTAlaunos Therapeutics$11K365.27N/AN/A$3.93 per share0.62XBIOXenetic Biosciences$2.58M1.74N/AN/A$6.36 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBXRXBaudax Bio-$58.79M-$9.23N/AN/AN/AN/AN/A-175.11%N/AEYENEyenovia-$27.26M-$58.40N/AN/AN/A-114,639.41%-1,108.24%-139.36%8/11/2025 (Estimated)TCRTAlaunos Therapeutics-$35.14MN/A0.00∞N/AN/A-267.77%-209.18%8/12/2025 (Estimated)XBIOXenetic Biosciences-$4.14M-$2.38N/AN/AN/A-161.63%-49.51%-43.99%8/12/2025 (Estimated)Latest BXRX, EYEN, XBIO, and TCRT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025EYENEyenovia-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million5/15/2025Q1 2025TCRTAlaunos Therapeutics-$4.50-$0.67+$3.83-$0.67N/A$0.00 million5/13/2025Q1 2025XBIOXenetic Biosciences-$0.72-$0.59+$0.13-$0.59$0.52 million$0.59 million3/18/2025Q4 2024XBIOXenetic Biosciences-$0.20-$0.68-$0.48-$0.68$0.18 million$0.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBXRXBaudax BioN/AN/AN/AN/AN/AEYENEyenoviaN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBXRXBaudax BioN/A0.070.07EYENEyenovia0.580.740.55TCRTAlaunos TherapeuticsN/A4.304.30XBIOXenetic BiosciencesN/A6.976.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBXRXBaudax Bio9.05%EYENEyenovia25.84%TCRTAlaunos Therapeutics27.72%XBIOXenetic Biosciences15.12%Insider OwnershipCompanyInsider OwnershipBXRXBaudax Bio0.10%EYENEyenovia7.10%TCRTAlaunos Therapeutics5.11%XBIOXenetic Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBXRXBaudax Bio952.46 million52.41 millionNot OptionableEYENEyenovia402.88 million1.29 millionOptionableTCRTAlaunos Therapeutics401.64 million1.52 millionNo DataXBIOXenetic Biosciences41.54 million1.32 millionNot OptionableBXRX, EYEN, XBIO, and TCRT HeadlinesRecent News About These CompaniesXenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | accessnewswire.comXenetic Biosciences (XBIO) Receives a Hold from H.C. WainwrightApril 10, 2025 | markets.businessinsider.comXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentApril 9, 2025 | accessnewswire.comXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentApril 9, 2025 | accessnewswire.comXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing SarcomaMarch 26, 2025 | accessnewswire.comXenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 20, 2025 | finance.yahoo.comXenetic Biosciences, Inc. Reports Full Year 2024 Financial ResultsMarch 19, 2025 | accessnewswire.comXenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic ResponsesMarch 13, 2025 | accessnewswire.comXenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy MeetingFebruary 27, 2025 | accessnewswire.comXenetic Biosciences extends research agreement with University of Virginia for the advancement of its DNase-based oncology platformDecember 18, 2024 | pharmabiz.comXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentDecember 17, 2024 | accesswire.comXenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology PlatformDecember 16, 2024 | accesswire.comXenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology ProgramDecember 5, 2024 | accesswire.comXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentNovember 22, 2024 | accesswire.comXenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung MetastasisNovember 21, 2024 | accesswire.comXenetic Biosciences, Inc. Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | accesswire.comXenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma ModelsNovember 12, 2024 | accesswire.comXenetic Biosciences Extends Drug Development Pact With Scripps Research InstituteNovember 9, 2024 | precisionmedicineonline.comXenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformNovember 7, 2024 | accesswire.comXenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024October 22, 2024 | accesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBXRX, EYEN, XBIO, and TCRT Company DescriptionsBaudax Bio NASDAQ:BXRXBaudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.Eyenovia NASDAQ:EYEN$1.70 -0.11 (-6.08%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.68 -0.02 (-1.47%) As of 05/30/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Alaunos Therapeutics NASDAQ:TCRT$2.45 -0.13 (-5.04%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.48 +0.02 (+1.02%) As of 05/30/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.Xenetic Biosciences NASDAQ:XBIO$2.91 -0.07 (-2.32%) Closing price 05/30/2025 03:39 PM EasternExtended Trading$2.98 +0.07 (+2.54%) As of 05/30/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
